发明名称 Anti-P-selectin antibodies
摘要 Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
申请公布号 US9068001(B2) 申请公布日期 2015.06.30
申请号 US201113204508 申请日期 2011.08.05
申请人 Selexys Pharmaceuticals;Oklahoma Medical Research Foundation 发明人 Rollins Scott;Alvarez Richard;Rother Russell;McEver Rodger P.;Kawar Ziad S.
分类号 A61K39/395;C07K16/28 主分类号 A61K39/395
代理机构 Giordano & Chavous LLC 代理人 Giordano & Chavous LLC
主权项 1. An isolated antibody or binding fragment thereof which specifically binds to a conformational epitope of P-selectin, wherein the conformational epitope is within amino acid positions 1-35 of SEQ ID NO:1, wherein the antibody or binding fragment thereof comprises the ability to block the binding of P-selectin glycoprotein ligand-1 (PSGL-1) to P-selectin; and wherein the antibody or binding fragment thereof further comprises the ability to cause dissociation of a preformed P-selectin-PSGL-1 complex, wherein the amino acids in amino acid positions 4, 14, 17, 21, and 22 are H, I, K, N, and R, respectively, provided that the antibody or binding fragment thereof is not G1 antibody, the G1 antibody comprising variable light chains each individually having an amino acid sequence selected from the group consisting of SEQ ID NOs: 45, 49, 51, 53, and 65, and further comprising variable heavy chains each individually having an amino acid sequence selected from the group consisting of SEQ ID NOs: 59, 63, and 67; further provided that the antibody or binding fragment thereof is not hSel001 antibody comprising variable light chains each individually having an amino acid sequence of SEQ ID NO:38 and variable heavy chains each individually having an amino acid sequence of SEQ ID NO:42; further provided that the antibody or binding fragment thereof is nota binding fragment of the G1 antibody; or a binding fragment of the hSe1001 antibody.
地址 Oklahoma City OK US